379 related articles for article (PubMed ID: 23368099)
1. Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.
Ziarek JJ; Liu Y; Smith E; Zhang G; Peterson FC; Chen J; Yu Y; Chen Y; Volkman BF; Li R
Curr Top Med Chem; 2012; 12(24):2727-40. PubMed ID: 23368099
[TBL] [Abstract][Full Text] [Related]
2. Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design.
Veldkamp CT; Ziarek JJ; Peterson FC; Chen Y; Volkman BF
J Am Chem Soc; 2010 Jun; 132(21):7242-3. PubMed ID: 20459090
[TBL] [Abstract][Full Text] [Related]
3. Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine.
Smith EW; Liu Y; Getschman AE; Peterson FC; Ziarek JJ; Li R; Volkman BF; Chen Y
J Med Chem; 2014 Nov; 57(22):9693-9. PubMed ID: 25356720
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Identification of Novel Ligands Targeting Multiple Sites within a Chemokine-G-Protein-Coupled-Receptor Interface.
Smith EW; Nevins AM; Qiao Z; Liu Y; Getschman AE; Vankayala SL; Kemp MT; Peterson FC; Li R; Volkman BF; Chen Y
J Med Chem; 2016 May; 59(9):4342-51. PubMed ID: 27058821
[TBL] [Abstract][Full Text] [Related]
5. Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine a as a new CXCR4 ligand exhibiting antagonist activity.
Vitale RM; Gatti M; Carbone M; Barbieri F; Felicità V; Gavagnin M; Florio T; Amodeo P
ACS Chem Biol; 2013 Dec; 8(12):2762-70. PubMed ID: 24102412
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Potential Chemical Probe as Inhibitors of CXCL12 Using Ligand-Based Virtual Screening and Molecular Dynamic Simulation.
Haider S; Barakat A; Ul-Haq Z
Molecules; 2020 Oct; 25(20):. PubMed ID: 33092204
[TBL] [Abstract][Full Text] [Related]
7. Molecular-Simulation-Driven Fragment Screening for the Discovery of New CXCL12 Inhibitors.
Martinez-Rosell G; Harvey MJ; De Fabritiis G
J Chem Inf Model; 2018 Mar; 58(3):683-691. PubMed ID: 29481075
[TBL] [Abstract][Full Text] [Related]
8. Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery.
Ziarek JJ; Getschman AE; Butler SJ; Taleski D; Stephens B; Kufareva I; Handel TM; Payne RJ; Volkman BF
ACS Chem Biol; 2013 Sep; 8(9):1955-63. PubMed ID: 23802178
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12.
Veldkamp CT; Seibert C; Peterson FC; De la Cruz NB; Haugner JC; Basnet H; Sakmar TP; Volkman BF
Sci Signal; 2008 Sep; 1(37):ra4. PubMed ID: 18799424
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.
Ziarek JJ; Kleist AB; London N; Raveh B; Montpas N; Bonneterre J; St-Onge G; DiCosmo-Ponticello CJ; Koplinski CA; Roy I; Stephens B; Thelen S; Veldkamp CT; Coffman FD; Cohen MC; Dwinell MB; Thelen M; Peterson FC; Heveker N; Volkman BF
Sci Signal; 2017 Mar; 10(471):. PubMed ID: 28325822
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines.
Hanes MS; Salanga CL; Chowdry AB; Comerford I; McColl SR; Kufareva I; Handel TM
J Biol Chem; 2015 Sep; 290(37):22385-97. PubMed ID: 26216880
[TBL] [Abstract][Full Text] [Related]
12. Interaction of chemokine receptor CXCR4 in monomeric and dimeric state with its endogenous ligand CXCL12: coarse-grained simulations identify differences.
Cutolo P; Basdevant N; Bernadat G; Bachelerie F; Ha-Duong T
J Biomol Struct Dyn; 2017 Feb; 35(2):399-412. PubMed ID: 26813575
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of the interactions between CXCR4 and CXCL12/SDF-1 revealed by theoretical approaches.
Xu L; Li Y; Sun H; Li D; Hou T
Mol Biosyst; 2013 Aug; 9(8):2107-17. PubMed ID: 23702796
[TBL] [Abstract][Full Text] [Related]
14. Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrow‑induced chemoresistance in acute leukemias.
Pillozzi S; Bernini A; Spiga O; Lelli B; Petroni G; Bracci L; Niccolai N; Arcangeli A
Oncol Rep; 2019 Jan; 41(1):312-324. PubMed ID: 30365110
[TBL] [Abstract][Full Text] [Related]
15. The good and bad faces of the CXCR4 chemokine receptor.
Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
[TBL] [Abstract][Full Text] [Related]
16. Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies.
Hatse S; Princen K; Liekens S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2004 Oct; 61(2):178-88. PubMed ID: 15382150
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
18. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
[TBL] [Abstract][Full Text] [Related]
19. Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors.
Mooring SR; Liu J; Liang Z; Ahn J; Hong S; Yoon Y; Snyder JP; Shim H
ChemMedChem; 2013 Apr; 8(4):622-32. PubMed ID: 23468189
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
